Inactive Instrument

HUTCHISON CHINA MED. Share Price London S.E.

Equities

Pharmaceuticals

Sales 2024 * 69Cr 5.77TCr Sales 2025 * 85Cr 7.09TCr Capitalization 307.37Cr 26TCr
Net income 2024 * -10Cr -876.75Cr Net income 2025 * - 0 EV / Sales 2024 * 4.08 x
Net cash position 2024 * 26Cr 2.14TCr Net cash position 2025 * 38Cr 3.2TCr EV / Sales 2025 * 3.17 x
P/E ratio 2024 *
-28.4 x
P/E ratio 2025 *
258 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 53.15%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 66 01/05/01
Director of Finance/CFO 57 01/08/01
Chief Tech/Sci/R&D Officer 59 01/22/01
Members of the board TitleAgeSince
Director/Board Member 73 01/17/01
Chairman 70 01/16/01
Director/Board Member 71 01/00/01
More insiders
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
More about the company